Organogenesis (ORGO) 10-Q 10 Aug 20 2020 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2020	Aug. 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	Organogenesis Holdings Inc.
Entity Central Index Key	0001661181
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Trading Symbol	ORGO
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Address, State or Province	MA
Title of 12(b) Security	Class A Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		105,417,168

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 40,455	$ 60,174
Restricted cash	299	196
Accounts receivable, net	44,024	39,359
Inventory	28,562	22,918
Prepaid expenses and other current assets	4,366	2,953
Total current assets	117,706	125,600
Property and equipment, net	53,033	47,184
Notes receivable from related parties	302	556
Intangible assets, net	19,164	20,797
Goodwill	25,539	25,539
Deferred tax asset	15	127
Other assets	728	884
Total assets	216,487	220,687
Current liabilities:
Deferred acquisition consideration	1,432	5,000
Current portion of term loan	6,667
Current portion of capital lease obligations	3,327	3,057
Accounts payable	29,944	28,387
Accrued expenses and other current liabilities	24,688	23,450
Total current liabilities	66,058	59,894
Line of credit	39,353	33,484
Term loan, net of current portion	52,954	49,634
Deferred rent	1,097	1,012
Capital lease obligations, net of current portion	13,011	14,431
Other liabilities	8,264	6,649
Total liabilities	180,737	165,104
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock, $0.0001 par value; 400,000,000 shares authorized; 106,145,716 and 105,599,434 shares issued; 105,417,168 and 104,870,886 shares outstanding at June 30, 2020 and December 31, 2019, respectively.	11	10
Additional paid-in capital	228,225	226,580
Accumulated deficit	(192,486)	(171,007)
Total stockholders' equity	35,750	55,583
Total liabilities and stockholders' equity	$ 216,487	$ 220,687

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	106,145,716	105,599,434
Common stock, shares outstanding	105,417,168	104,870,886

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net revenue	$ 68,960	$ 64,948	$ 130,692	$ 122,071
Cost of goods sold	20,042	19,446	38,835	36,426
Gross profit	48,918	45,502	91,857	85,645
Operating expenses:
Selling, general and administrative	46,502	48,957	99,115	97,850
Research and development	4,668	3,864	10,078	7,235
Total operating expenses	51,170	52,821	109,193	105,085
Loss from operations	(2,252)	(7,319)	(17,336)	(19,440)
Other expense, net:
Interest expense, net	(2,912)	(2,187)	(5,422)	(3,965)
Loss on the extinguishment of debt				(1,862)
Gain on settlement of deferred acquisition consideration			1,295
Other income (expense), net	25	(120)	46	12
Total other expense, net	(2,887)	(2,307)	(4,081)	(5,815)
Net loss before income taxes	(5,139)	(9,626)	(21,417)	(25,255)
Income tax expense	(27)	(23)	(62)	(60)
Net loss	$ (5,166)	$ (9,649)	$ (21,479)	$ (25,315)
Net loss per share—basic and diluted	$ (0.05)	$ (0.11)	$ (0.21)	$ (0.28)
Weighted-average common shares outstanding—basic and diluted	104,714,725	90,647,352	104,600,825	90,625,850

CONSOLIDATED STATEMENTS OF REDE

CONSOLIDATED STATEMENTS OF REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Revision of Prior Period, Accounting Standards Update, Adjustment [Member]	Redeemable Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated DeficitRevision of Prior Period, Accounting Standards Update, Adjustment [Member]
Balance at Dec. 31, 2018	$ 47,041	$ 332		$ 9	$ 177,272	$ (130,240)	$ 332
Balance (in shares) at Dec. 31, 2018			728,548	91,261,413
Exercise of common stock warrants	628				628
Exercise of common stock warrants (in shares)				54,626
Exercise of stock options	54				54
Exercise of stock options (in shares)				26,683
Stock-based compensation expense	458				458
Redemption of redeemable common stock placed into treasury (Shares)			(728,548)
Net loss	(25,315)					(25,315)
Balance at Jun. 30, 2019	23,198			$ 9	178,412	(155,223)
Balance (in shares) at Jun. 30, 2019				91,342,722
Balance at Mar. 31, 2019	32,559			$ 9	178,124	(145,574)
Balance (in shares) at Mar. 31, 2019				91,316,039
Exercise of stock options	54				54
Exercise of stock options (in shares)				26,683
Stock-based compensation expense	234				234
Net loss	(9,649)					(9,649)
Balance at Jun. 30, 2019	23,198			$ 9	178,412	(155,223)
Balance (in shares) at Jun. 30, 2019				91,342,722
Balance at Dec. 31, 2019	$ 55,583			$ 10	226,580	(171,007)
Balance (in shares) at Dec. 31, 2019	104,870,886			104,870,886
Exercise of stock options	$ 968			$ 1	967
Exercise of stock options (in shares)	546,282			546,282
Stock-based compensation expense	$ 678				678
Net loss	(21,479)					(21,479)
Balance at Jun. 30, 2020	$ 35,750			$ 11	228,225	(192,486)
Balance (in shares) at Jun. 30, 2020	105,417,168			105,417,168
Balance at Mar. 31, 2020	$ 40,295			$ 11	227,604	(187,320)
Balance (in shares) at Mar. 31, 2020				105,360,015
Exercise of stock options	152				152
Exercise of stock options (in shares)				57,153
Stock-based compensation expense	469				469
Net loss	(5,166)					(5,166)
Balance at Jun. 30, 2020	$ 35,750			$ 11	$ 228,225	$ (192,486)
Balance (in shares) at Jun. 30, 2020	105,417,168			105,417,168

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (21,479)	$ (25,315)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,793	1,761
Amortization of intangible assets	1,633	2,997
Non-cash interest expense	103	154
Deferred interest expense	1,022	536
Deferred rent expense	64	326
Gain on settlement of deferred acquisition consideration	(1,295)
Provision recorded for sales returns and doubtful accounts	970	27
Loss on disposal of property and equipment	201
Adjustment for excess and obsolete inventories	1,709	523
Stock-based compensation	678	458
Loss on extinguishment of debt		1,862
Changes in operating assets and liabilities:
Accounts receivable	(5,727)	723
Inventory	(7,353)	(6,087)
Prepaid expenses and other current assets	(1,302)	(785)
Accounts payable	235	1,473
Accrued expenses and other current liabilities	1,266	122
Other liabilities	864	(449)
Net cash used in operating activities	(26,618)	(21,674)
Cash flows from investing activities:
Purchases of property and equipment	(6,411)	(1,251)
Proceeds from the repayment of notes receivable from related parties	293
Acquisition of intangible asset		(250)
Net cash used in investing activities	(6,118)	(1,501)
Cash flows from financing activities:
Line of credit borrowings	5,869	7,000
Proceeds from term loan	10,000	40,000
Repayment of notes payable		(17,585)
Proceeds from the exercise of stock options	968	54
Proceeds from the exercise of common stock warrants		628
Redemption of redeemable common stock placed into treasury		(6,762)
Principal repayments of capital lease obligations	(1,149)	(557)
Payment of deferred acquisition consideration	(2,568)
Payment of debt issuance costs		(849)
Net cash provided by financing activities	13,120	21,929
Change in cash and restricted cash	(19,616)	(1,246)
Cash and restricted cash, beginning of period	60,370	21,405
Cash and restricted cash, end of period	40,754	20,159
Supplemental disclosure of cash flow information:
Cash paid for interest	4,626	3,890
Cash paid for income taxes		67
Supplemental disclosure of non-cash investing and financing activities:
Debt issuance costs included in accounts payable		75
Purchases of property and equipment included in accounts payable and accrued expenses	$ 4,692	1,638
Amounts due related to acquisition of intangible assets included in accrued expenses and other liabilities		$ 500

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation Organogenesis Holdings Inc. (formerly Avista Healthcare Public Acquisition Corp.) (“ORGO” or the “Company”) is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Many of the existing and pipeline products in the Company’s portfolio have Premarket Application approval, Business License Applicant approval or Premarket Notification 510(k) clearance from the United States Food and Drug Administration (“FDA”). The Company’s customers include hospitals, wound care centers, government facilities, ambulatory service centers (“ASCs”) and physician offices. The Company has one operating and reportable segment. COVID-19 The emergence of the coronavirus (COVID-19) COVID-19 COVID-19 COVID-19 The Company is closely monitoring the evolving impact of the pandemic on all aspects of its business. The Company has implemented a number of measures designed to protect the health and safety of its employees, support its customers and promote business continuity. The Company is also actively reviewing and implementing cost-saving measures including discontinuing or delaying all non-essential COVID-19 Merger with Avista Healthcare Public Acquisition Corp On December 10, 2018, Avista Healthcare Public Acquisition Corp., our predecessor company (“AHPAC”), consummated the previously announced merger (the “Avista Merger”) pursuant to an Agreement and Plan of Merger, dated as of August 17, 2018 (as amended, the “Avista Merger Agreement”), by and among AHPAC, Avista Healthcare Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of AHPAC (“Avista Merger Sub”) and Organogenesis Inc., a Delaware corporation (“Organogenesis Inc.”). As a result of the Avista Merger and the other transactions contemplated by the Avista Merger Agreement, Avista Merger Sub merged with and into Organogenesis Inc., with Organogenesis Inc. surviving the Avista Merger and becoming a wholly-owned subsidiary of AHPAC. AHPAC changed its name to Organogenesis Holdings Inc. (ORGO). The Avista Merger was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Under this method of accounting, AHPAC was treated as the “acquired” company for accounting purposes. This determination was primarily based on Organogenesis Inc.’s equity holders having a majority of the voting power of the combined company, Organogenesis Inc. comprising the ongoing operations of the combined entity, Organogenesis Inc. comprising a majority of the governing body of the combined company, and Organogenesis Inc.’s senior management comprising the senior management of the combined company. Accordingly, for accounting purposes, the Avista Merger was treated as the equivalent of Organogenesis Inc. issuing stock for the net assets of AHPAC, accompanied by a recapitalization. The net assets of AHPAC were recorded at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Avista Merger are those of Organogenesis Inc. Liquidity and Financial Conditions In accordance with ASC 205-40, Going Concern 205-40”), COVID-19 The Company expects to continue investing in product development, sales and marketing, and customer support for its products. The Company may seek to raise additional funding through public and/or private equity financings, debt financings, or other strategic transactions. There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company, on a timely basis or at all, particularly in light of the adverse impacts of the COVID-19 Non-PuraPly COVID-19

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying unaudited consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America and in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. While we believe that the disclosures presented are adequate in order to make the information not misleading, these unaudited quarterly financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K The unaudited consolidated financial statements include the accounts and results of operations of Organogenesis Holdings Inc. and its wholly-owned or controlled subsidiaries of Organogenesis Inc., including Organogenesis GmbH (a Switzerland corporation) and Prime Merger Sub, LLC. All intercompany balances and transactions have been eliminated in consolidation. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. In the opinion of management, the unaudited consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s financial position, results of operations and cash flows at the dates and for the periods indicated. The results for the six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020, any other interim periods, or any future years or periods. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure as of the date of the consolidated financial statements and the reported results of operations during the reporting period. Actual results could differ from those estimates. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note “2. Significant Accounting Policies” to the Consolidated Financial Statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report. Recently Issued Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), which ASU 2018-10, Codification Improvements to Topic 842, Leases ASU 2016-02, and ASU 2018-11, Leases (Topic 842): Targeted Improvements ASU 2016-02, and ASU 2019-01, Leases (Topic 842): Codification Improvements ASU 2016-02 and a right-of-use asset In June 2016, the FASB issued ASU 2016-13 , Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Subsequent ASU 2016-13, the ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments- Credit Losses ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ASU 2019-05, Financial Instruments—Credit Losses (Topic 326)—Targeted Transition Relief ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses ASU 2016-13 and ASU 2016-13 and ASU 2016-13 and

Product and Geographic Sales

Product and Geographic Sales	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Product and Geographic Sales	3. Product and Geographic Sales The Company generates revenue through the sale of Advanced Wound Care and Surgical & Sports Medicine products. There is a single performance obligation in all of the Company’s contracts, which is the Company’s promise to transfer the Company’s products to customers based on specific payment and shipping terms in the arrangement. The entire transaction price reflects a single performance obligation. Product revenue is recognized when a customer obtains control of the Company’s products which occurs at a point in time and may be upon shipment, procedure date, or delivery, based on the terms of the contract. Revenue is recorded net of a reserve for returns, discounts and Group Purchasing Organization (“GPO”) rebates, which represent a direct reduction to the revenue recognized. These reductions are accrued at the time revenue is recognized, based upon historical experience and specific circumstances. For the three months ended June 30, 2020 and 2019, the Company recorded GPO fees of $837 and $731, respectively, as a direct reduction of revenue. For the six months ended June 30, 2020 and 2019, the Company recorded GPO fees of $1,797 and $1,111, respectively, as a direct reduction of revenue. The following tables set forth revenue by product category: Three Months Ended June 30, 2020 2019 Advanced Wound Care $ 59,731 $ 55,211 Surgical & Sports Medicine 9,229 9,737 Total net revenue $ 68,960 $ 64,948 Six Months Ended June 30, 2020 2019 Advanced Wound Care $ 111,019 $ 103,055 Surgical & Sports Medicine 19,673 19,016 Total net revenue $ 130,692 $ 122,071 For the three months ended June 30, 2020 and 2019, net PuraPly revenue totaled $28,519 and $29,691, respectively. For the six months ended June 30, 2020 and 2019, net PuraPly revenue totaled $61,024 and $55,138, respectively. For all periods presented, net revenue generated outside the United States represented less than 1% of total net revenue.

Accounts receivable, net

Accounts receivable, net	6 Months Ended
	Jun. 30, 2020
Receivables [Abstract]
Accounts receivable, net	4. Accounts Receivable, Net Accounts receivable consisted of the following: June 30, December 31, 2020 2019 Accounts receivable $ 47,952 $ 42,408 Less — allowance for sales returns and doubtful accounts (3,928 ) (3,049 ) $ 44,024 $ 39,359 The Company’s allowance for sales returns and doubtful accounts was comprised of the following: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Balance at beginning of period $ 3,204 $ 3,292 $ 3,049 $ 3,420 Additions (reductions) 753 103 970 27 Write-offs (29 ) (374 ) (91 ) (426 ) Balance at end of period $ 3,928 $ 3,021 $ 3,928 $ 3,021

Inventories

Inventories	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories	5. Inventories Inventories, net of related reserves for excess and obsolescence, consisted of the following: June 30, December 31, 2020 2019 Raw materials $ 9,591 $ 9,178 Work in process 1,559 781 Finished goods 17,412 12,959 $ 28,562 $ 22,918 Raw materials include various components used in the Company’s manufacturing process. The Company’s excess and obsolete inventory review process includes analysis of sales forecasts and historical sales as compared to inventory level, and working with operations to maximize recovery of excess inventory. During the three months ended June 30, 2020 and 2019, the Company charged $940 and $265, respectively, for inventory excess and obsolescence to cost of goods sold within the consolidated statements of operations. During the six months ended June 30, 2020 and 2019, the Company charged $1,709 and $523, respectively, for inventory excess and obsolescence to cost of goods sold within the consolidated statements of operations.

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	6. Property and Equipment, Net Property and equipment consisted of the following: June 30, December 31, 2020 2019 Leasehold improvements $ 38,807 $ 36,344 Furniture, computers and equipment 47,352 46,430 86,159 82,774 Accumulated depreciation and amortization (67,604 ) (65,812 ) Construction in progress 34,478 30,222 $ 53,033 $ 47,184 Depreciation expense was $891 and $859 for the three months ended June 30, 2020 and 2019. Depreciation expense was $1,793 and $1,761 for the six months ended June 30, 2020 and 2019. As of June 30, 2020 and December 31, 2019, the Company had $21,689 of buildings under capital leases recorded within leasehold improvements. As of June 30, 2020 and December 31, 2019, the Company had $14,376 and $13,777 recorded within accumulated depreciation and amortization related to buildings under capital leases, respectively. Construction in progress primarily represents unfinished construction work on a building under a capital lease and, more recently, improvements at the Company’s leased facilities in Canton and Norwood, Massachusetts.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets Goodwill was $25,539 as of June 30, 2020 and December 31, 2019. There were no impairments recorded against goodwill during the three and six months ended June 30, 2020 and 2019. In April 2019, the Company purchased $750 of intangibles related to patent and know-how Original Accumulated Net Book Cost Amortization Value Developed technology $ 30,570 $ (12,748 ) $ 17,822 Trade names and trademarks 2,000 (766 ) 1,234 Non-compete 260 (152 ) 108 Total $ 32,830 $ (13,666 ) $ 19,164 Identifiable intangible assets consisted of the following as of December 31, 2019: Original Accumulated Net Book Cost Amortization Value Developed technology $ 30,570 $ (11,266 ) $ 19,304 Trade names and trademarks 2,000 (650 ) 1,350 Non-compete 260 (117 ) 143 Total $ 32,830 $ (12,033 ) $ 20,797 Amortization of intangible assets, calculated on a straight-line basis or using an accelerated method, was $816 and $1,499 for the three months ended June 30, 2020 and 2019, respectively and $1,633 and $2,997 for the six months ended June 30, 2020 and 2019, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: June 30, December 31, 2020 2019 Accrued personnel costs $ 19,062 $ 17,640 Other 5,626 5,810 $ 24,688 $ 23,450

Long-Term Debt Obligations

Long-Term Debt Obligations	6 Months Ended
	Jun. 30, 2020
Long-term Debt, Unclassified [Abstract]
Long-Term Debt Obligations	9. Long-Term Debt Obligations Long-term debt obligations consisted of the following: June 30, December 31, 2020 2019 Line of credit $ 39,353 $ 33,484 Term loan 60,000 50,000 Less debt discount and debt issuance cost (379 ) (366 ) Less current maturities (6,667 ) — Term loan, net of debt discount, debt issuance cost and current maturities $ 52,954 $ 49,634 2019 Credit Agreement In March 2019, the Company, its subsidiaries and Silicon Valley Bank (“SVB”), and the several other lenders thereto (collectively, the “Lenders”) entered into a credit agreement, as amended (the “2019 Credit Agreement”), providing for a term loan (the “Term Loan Facility”) and a revolving credit facility (the “Revolving Facility”) in an aggregate principal amount of $100,000. Capitalized terms used herein and not otherwise defined are defined as set forth in the 2019 Credit Agreement. The Term Loan Facility is structured in three tranches, as follows: (i) the first tranche of $40,000 was made available to the Company and fully funded on March 14, 2019; (ii) the second tranche of $10,000 was made available to the Company and fully funded in September 2019 upon achievement of certain financial metrics; and (iii) the third tranche of $10,000 was made available to the Company and fully funded in March 2020 upon achievement of a certain financial metric. The interest rate for the Term Loan Facility is a floating per annum interest rate equal to the greater of 3.75% above the Wall Street Journal Prime Rate and 9.25%. The interest rate as of June 30, 2020 was 9.25%. The 2019 Credit Agreement requires the Company to make monthly interest-only payments on outstanding balances under the Term Loan Facility through February 2021. Thereafter, each term loan advance will be repaid in thirty-six The Company’s final payment on the Term Loan Facility, due on the Term Loan Maturity Date, will include all outstanding principal and accrued and unpaid interest under the Term Loan Facility, plus a final payment (the “Final Payment”) equal to the original aggregate principal amount of the Term Loan Facility multiplied by 6.5%. The Company may prepay the Term Loan Facility, subject to paying the Prepayment Premium (described below) and the Final Payment. The Prepayment Premium is equal to 2.50% of the outstanding principal amount of the Term Loan Facility if the prepayment occurs after the one year anniversary and prior to the second anniversary of the closing, and 1.50% of the outstanding principal amount of the Term Loan Facility if the prepayment occurs after the two year anniversary but prior to the three year anniversary of the closing, and 0.50% thereafter. Once repaid, amounts borrowed under the Term Loan Facility may not be re-borrowed. The Revolving Facility is equal to the lesser of $40,000 and the amount determined by the Borrowing Base, which is defined as a percentage of the Company’s book value of qualifying finished goods inventory and eligible accounts receivable. The interest rate for advances under the Revolving Facility is a floating per annum interest rate equal to the greater of the Wall Street Journal Prime Rate and 5.50%. The interest rate as of June 30, 2020 was 5.50%. If the actual outstanding advances are less than 25% of the then-available Revolving Commitments, the Company must pay monthly interest equal to the interest that would have accrued if the average outstanding advances had been 25% of the then-available Revolving Commitments. The Company is also required to pay an unused line fee equal to 0.25% per annum, calculated based on the difference of $40,000 minus The Company may elect to reduce or terminate the Revolving Facility in its entirety at any time by repaying all outstanding principal, unpaid accrued interest and a reduction or termination fee equal to 3.00% of the aggregate Revolving Commitments so reduced or terminated if the reduction or termination occurs after the one year anniversary and prior to the second anniversary of the closing, and 2.00% of the aggregate Revolving Commitments so reduced or terminated if the reduction or termination occurs after the two year anniversary but prior to the three year anniversary of the closing, and $0 thereafter. The Company is required to achieve certain financial covenants under the 2019 Credit Agreement, including Minimum Trailing Twelve Month Consolidated Revenue and Non-PuraPly Non-PuraPly As of June 30, 2020, the Company was in compliance with the financial covenants under the 2019 Credit Agreement. As of June 30, 2020, the Company had outstanding borrowings of $60,000 under the Term Loan Facility and $39,353 under the Revolving Facility with $0 available for future revolving borrowings. The Company accrues for the Final Payment of $3,900 over the term of the Term Loan Facility through a charge to the interest expense. The related liability of $1,225 and $681 as of June 30, 2020 and December 31, 2019, respectively, was included in other liabilities in the consolidated balance sheets. The Company incurred costs of $554 in connection with the Term Loan Facility, which are recorded as a reduction of the carrying value of the term loan on the Company’s consolidated balance sheet. In connection with the Revolving Facility, the Company incurred costs of $370, which are recorded as other assets. Both of these costs are being amortized to interest expense through March 1, 2024. Future payments of the 2019 Credit Agreement, as of June 30, 2020, are as follows for the calendar years ending December 31: 2020 $ — 2021 16,667 2022 20,000 2023 20,000 2024 42,686 Total $ 99,353 2017 Credit Agreement On March 21, 2017, the Company entered into a credit agreement (the “2017 Credit Agreement”) with SVB whereby SVB agreed to extend to the Company a revolving credit facility in an aggregate amount not to exceed $30,000 with a letter of credit sub-facility sub-facility sub-facilities On March 14, 2019, $26,541, representing all outstanding unpaid principal and accrued interest relating to the revolving borrowing due under the 2017 Credit Agreement, was rolled into the 2019 Credit Agreement. Master Lease Agreement On April 28, 2017, the Company entered into the Master Lease Agreement (the “ML Agreement”) with Eastward Fund Management LLC that allowed the Company to borrow up to $20,000 on or prior to June 30, 2018. If the Company elected to prepay the loan or terminated the loan early within the first 24 months, the Company was required to pay an additional 3% of the outstanding principal and any accrued and unpaid interest and fees. This prepayment fee decreased to 2% after the first 24 months. A final payment fee of 6.5% multiplied by the principal amount of the borrowings under the ML Agreement was due upon the earlier to occur of the first day of the final payment term month or prepayment of all outstanding principal. In March 2019, upon entering into the 2019 Credit Agreement, the Company paid an aggregate amount of $17,649 due under the ML Agreement, including unpaid principal, accrued interest, final payment, and early termination penalty, with proceeds from the 2019 Credit Agreement, and the ML Agreement was terminated. Upon termination of the ML Agreement, the Company recognized $1,862 as loss on the extinguishment of the loan.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Common Stock As of June 30, 2020, the Company was authorized to issue 400,000,000 shares of $0.0001 par value Class A common stock and 1,000,000 shares of $0.0001 par value preferred stock. 106,145,716 shares of Class A common stock were issued as of June 30, 2020, which included 728,548 shares of treasury stock. These treasury shares were initially issued in connection with the acquisition of Nutech Medical, Inc. (“NuTech Medical”) in 2017 and included a put right. The holders of the shares exercised the right to put the shares back to the Company at an agreed-upon exercise price of $9.28 per share on March 24, 2019. As of June 30, 2020 and December 31, 2019, the Company reserved the following shares of Class A common stock for future issuance: June 30, December 31, 2020 2019 Shares reserved for issuance for outstanding options 7,161,316 6,503,646 Shares reserved for issuance for outstanding restricted stock units 858,095 — Shares reserved for issuance for future grants 6,612,178 9,008,996 Total shares of authorized common stock reserved for future issuance 14,631,589 15,512,642

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation Stock Incentive Plans-the On November 28, 2018, the Board of Directors of the Company adopted, and on December 10, 2018 the Company’s stockholders approved, the Organogenesis 2018 Equity and Incentive Plan (the “2018 Plan”). The purposes of the 2018 Plan are to provide long-term incentives and rewards to the Company’s employees, officers, directors and other key persons (including consultants), to attract and retain persons with the requisite experience and ability, and to more closely align the interests of such employees, officers, directors and other key persons with the interests of the Company’s stockholders. The 2018 Plan authorizes the Company’s Board of Directors or a committee of not less than two independent directors (in either case, the “Administrator”) to grant the following types of awards: non-statutory As of June 30, 2020, a total of 9,198,996 shares of Class A common stock have been authorized to be issued under the 2018 Plan (subject to adjustment in the case of any stock dividend, stock split, reverse stock split, or similar change in capitalization of the Company). Stock Incentive Plans-the The Organogenesis 2003 Stock Incentive Plan (the “2003 Plan”), provides for the Company to issue restricted stock awards, or to grant incentive stock options or non-statutory non-statutory Effective as of the closing of the Avista Merger on December 10, 2018, no additional awards may be made under the 2003 Plan and as a result (i) any shares in respect of stock options that are expired or terminated under the 2003 Plan without having been fully exercised will not be available for future awards; (ii) any shares in respect of restricted stock that are forfeited to, or otherwise repurchased by the Company, will not be available for future awards; and (iii) any shares of common stock that are tendered to the Company by a participant to exercise an award will not be available for future awards. Following the closing of the Avista Merger, the 2003 Plan is administered by the Company’s Board of Directors. Stock-Based Compensation Expense Stock options awarded under the stock incentive plans expire 10 years after the grant date and typically vest over four or five years. Restricted stock units awarded typically vest over four years. Stock-based compensation expense was $469 and $234 for the three months ended June 30, 2020 and 2019, respectively, and was $678 and $458 for the six months ended June 30, 2020 and 2019, respectively. The total amount of stock-based compensation expense was included within selling, general and administrative on the consolidated statements of operations. Restricted Stock Units In the six months ended June 30, 2020, the Company granted 873,595 time-based restricted stock units to its employees, executives and the Board of Directors. Each restricted stock unit represents the contingent right to receive one share of the Company’s common stock. A majority of the restricted stock units will vest in four equal annual installments in 2021, 2022, 2023 and 2024. The fair value of the restricted stock units was based on the fair market value of the Company’s stock on the date of grant. The activity of restricted stock units is set forth below: Number Weighted Unvested at December 31, 2019 — $ — Granted 873,595 3.81 Vested — — Canceled/Forfeited (15,500 ) 4.04 Unvested at June 30, 2020 858,095 $ 3.81 As of June 30, 2020, total unrecognized compensation cost related to unvested restricted stock units expected to vest was $2,245 and the weighted average remaining recognition period for unvested awards was 3.42 years. Stock Option Activity The following table summarizes the Company’s stock option activity since December 31, 2019: Weighted Average Weighted Remaining Average Contractual Aggregate Number of Exercise Term Intrinsic Shares Price (in years) Value Outstanding as of December 31, 2019 7,179,636 $ 1.98 5.06 $ 20,799 Granted 1,538,723 4.04 Exercised (546,282 ) 1.77 1,552 Canceled / forfeited (334,771 ) 3.48 Outstanding as of June 30, 2020 7,837,306 2.34 5.90 12,933 Options exercisable as of June 30, 2020 5,492,502 1.59 4.44 12,694 Options vested or expected to vest as of June 30, 2020 7,326,832 $ 2.21 5.65 $ 12,904 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s Class A common stock for those stock options that have exercise prices lower than the fair value of the Company’s Class A common stock. The total fair value of options vested during the six months ended June 30, 2020 and 2019 was $209 and $344, respectively. As of June 30, 2020, the total unrecognized stock compensation expense related to unvested stock options expected to vest was $2,047 and was expected to be recognized over a weighted-average period of 2.94 years. As of June 30, 2020, there were partial recourse notes outstanding totaling $635. These notes were taken by a former executive to exercise his stock options between 2011 and 2013 (see Note “14. Related Parties Transactions”) and the notes are secured with the 675,990 shares held by the former executive. As the loans are still outstanding, the options are not considered exercised and are included within the options outstanding. Accordingly, the 675,990 shares are not considered outstanding for accounting purposes and the additional paid-in

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	12. Net Loss per Share The Company’s potentially dilutive securities, which include stock options, restricted stock units and warrants to purchase shares of Class A common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of Class A common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to the common stockholders of Organogenesis Holdings Inc. for the periods indicated because including them would have had an anti-dilutive effect: Six Months Ended June 30, 2020 2019 Options to purchase common stock 7,837,306 7,328,352 Restricted stock units 858,095 — Warrants to purchase common stock — 17,678,074 8,695,401 25,006,426

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure	13. Commitments and Contingencies Capitalized Leases On January 1, 2013, the Company entered into capital lease arrangements with 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC and 275 Dan Road SPE, LLC for office and laboratory space in Canton, Massachusetts. 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC and 275 Dan Road SPE, LLC are related parties as the owners of these entities are also stockholders of the Company. The leases terminate on December 31, 2022 and each contains a renewal option for a five-year period with the rental rate at the greater of (i) rent for the last year of the prior term, or (ii) the then fair market value. Notice of the exercise of this renewal option is due one year prior to the expiration of the initial term. Aggregate annual lease payments are approximately $4,308 with future rent increases of 10% effective January 1, 2022. The Company records the capital lease asset within property and equipment and the liability is recorded within the capital lease obligations on the consolidated balance sheets. As of June 30, 2020 and December 31, 2019, the Company owed an aggregate of $10,336 of accrued but unpaid lease obligations, which are subordinated to the 2019 Credit Agreement and will not be paid until the debt under the 2019 Credit Agreement is paid off in 2024 even though the capital leases expire in December 2022. The accrued but unpaid lease obligations include rent in arrears and unpaid operating and common area maintenance costs under the aforementioned leases. The principal portion of rent in arrears on the capital leases totaled $6,631 and $6,321 as of June 30, 2020 and December 31, 2019, respectively, and is included in the long-term portion of capital lease obligations. The interest portion of rent in arrears totaled $3,208 and $3,512 as of June 30, 2020 and December 31, 2019, respectively, and is included in other liabilities on the consolidated balance sheets. The unpaid operating and common area maintenance costs totaled $497 and $503 as of June 30, 2020 and December 31, 2019, respectively, and are included in other liabilities on the consolidated balance sheets. Effective April 1, 2019, the Company agreed to accrue interest on the accrued but unpaid lease obligations at an interest rate equal to the rate charged in the 2019 Credit Agreement (see Note “9. Long-Term Debt Obligations”). The accrued interest is also subordinated to the 2019 Credit Agreement and, as such, is included in other liabilities on the consolidated balance sheet. Interest accrual as of June 30, 2020 and December 31, 2019 totaled $1,195 and $717, respectively. In addition to the capital leases with affiliates discussed above, the Company also has certain insignificant capital leases with non-affiliates. Future 2020 (remaining 6 months) $ 2,396 2021 4,786 2022 4,945 2023 — 2024 9,839 21,966 Less amount representing interest (5,628 ) Present value of minimum lease payments 16,338 Less current maturities (3,327 ) Long-term portion $ 13,011 Operating Leases The Company leases vehicles for certain employees and has fleet services agreements for service on these vehicles. The minimum lease term for each newly leased vehicle is one year with three consecutive one-year In March 2014, in conjunction with the acquisition of Dermagraft from Shire plc, the Company entered into a rental sublease agreement for certain operating and office space in California. The sublease agreements called for escalating monthly rental payments and expires in December 2021. In conjunction with the acquisition of NuTech Medical in March 2017, the Company entered into an operating lease with Oxmoor Holdings, LLC, an entity that is affiliated with the former sole shareholder of NuTech Medical, related to the facility at NuTech Medical’s headquarters in Birmingham, Alabama. Under the lease, the Company is required to make monthly rent payments of approximately $21 through the lease termination date on December 31, 2021. In March 2019, the Company entered into an agreement to lease approximately 43,850 square feet of office and laboratory space in Norwood, Massachusetts. Pursuant to the lease agreement, the rent commencement date is February 1, 2020. The initial lease term is ten years from the rent commencement date and includes an option for an early extension term of five years which is exercisable during the first two years after the rent commencement date. In addition to the early extension term, the lease provides the Company with an option to extend the lease term for a period of ten years, if exercised, at rental rates equal to the then fair market value. Annual lease payments during the first year are $1,052 with increases of $44 each year during the initial ten-year Operating lease expenses were $1,837 and $1,603 for the three months ended June 30, 2020 and 2019, respectively and were $3,351 and $2,925 for the six months ended June 30, 2020 and 2019, respectively. Future minimum lease payments due under noncancelable operating lease agreements as of June 30, 2020 are as follows: 2020 (remaining 6 months) $ 2,884 2021 5,627 2022 3,094 2023 2,361 2024 1,224 Thereafter 6,899 $ 22,089 Royalty Commitments The Company entered into a license agreement with a university for certain patent rights related to the development, use, and production of one of its advanced wound care products. Under this agreement, the Company incurred a royalty based on a percentage of net product sales, for the use of these patents until the patents expired, which was in November 2006. Accrued royalties totaled $1,187 as of June 30, 2020 and December 31, 2019, respectively, and are classified as part of accrued expenses on the Company’s consolidated balance sheets. There was no royalty expense incurred during the three and six months ended June 30, 2020 or 2019 related to this agreement. In October 2017, the Company entered into a license agreement with a third party. Under the license agreement, the Company is required to pay royalties based on a percentage of net sales of the licensed product that occur, after December 31, 2017, through the expiration of the underlying patent in October 2026, subject to minimum royalty payment provisions. The Company recorded royalty expense of $839 and $916 during the three months ended June 30, 2020 and 2019, respectively and $1,819 and $1,704 during the six months ended June 30, 2020 and 2019, respectively, within selling, general and administrative expenses on the consolidated statement of operations. As part of the NuTech Medical acquisition, the Company inherited certain product development and consulting agreements for ongoing consulting services and royalty payments based on a percentage of net sales on certain products over a period of 15 years from the execution of the agreements. These product development and consulting agreements were cancelled in January 2020 for a total consideration of $1,950 that was paid on February 14, 2020. The $1,950 cancellation fee was recorded within selling, general and administration in the consolidated statement of operations for the six months ended June 30, 2020. Legal Proceedings In conducting its activities, the Company, from time to time, is subject to various claims and also has claims against others. In management’s opinion, the ultimate resolution of such claims would not have a material effect on the financial position, operating results or cash flows of the Company. The Company accrues for these claims when amounts due are probable and estimable. The Company accrued $1,109 and $542 as of June 30, 2020 and December 31, 2019, respectively, in relation to certain pending lawsuits. The purchase price for NuTech Medical acquired in 2017 included $7,500 deferred acquisition consideration of which the Company paid $2,500 in 2017. The amount of the remaining $5,000 of deferred acquisition consideration plus accrued interest owed to the sellers of NuTech Medical was previously in dispute. The Company asserted certain claims for indemnification that would offset in whole or in part its payment obligation and the sellers of NuTech Medical filed a lawsuit alleging breach of contract and seeking specific performance of the alleged payment obligation and attorneys’ fees. In February 2020, the Company entered into a settlement agreement with the sellers of NuTech Medical and settled the dispute for $4,000, of which, $2,000 was paid immediately on February 24, 2020 (the “Settlement Date”) and the remaining $2,000 is paid in four quarterly installments of $500 each with the first quarterly payment due and payable on the date that is 90 days from the Settlement Date. In addition, the Company assumed from the sellers of NuTech Medical the payment responsibilities related to a legacy lawsuit of NuTech Medical. In connection with the settlement, the Company recorded a gain of $1,295 which was included as a component of other expense, net, in the consolidated statement of operations for the six months ended June 30, 2020.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	14. Related Party Transactions Capital lease obligations to affiliates, including unpaid lease obligations, and an operating lease with affiliates are further described in Note “13. Commitments and Contingencies”. During 2010, the Company’s Board of Directors approved a loan program that permitted the Company to make loans to three executives of the Company (the “Employer Loans”) to (i) provide them with liquidity (“Liquidity Loans”) and (ii) fund the exercise of vested stock options (“Option Loans”). The Employer Loans mature with all principal and accrued interest due on the tenth anniversary of the issuance date of each subject loan, except that in certain circumstances, the Employer Loans may mature earlier. The borrower may prepay all or any portion of his Employer Loan at any time without premium or penalty. Interest on the Employer Loans accrues at various rates ranging from 2.30%—3.86% per annum, compounded annually. The Employer Loans are secured by 1,739,088 and 675,990 shares of the Company’s Class A common stock held by two former executives, respectively. With respect to the Liquidity Loans, the Company has no personal recourse against the borrowers beyond the pledged shares. As of June 30, 2020 and December 31, 2019, Liquidity Loans to two former executives were outstanding with an aggregate principal balance of $2,350 and Option Loans to one former executive were outstanding with an aggregate principal balance of $635 The principal and part of the interest receivable under the Employer Loans were fully reserved with net interest receivable of $302 and $556 as of June 30, 2020 and December 31, 2019, respectively, included in the notes receivable from related parties balance in the consolidated balance sheets. The decrease in the interest receivable is due to a partial payment in June 2020 by one of the former executives. Interest income related to these notes was $20 and $20 for the three months ended June 30, 2020 and 2019 and $40 and $39 for the six months ended June 30, 2020 and 2019, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events The Company has evaluated subsequent events through August 10, 2020, the date on which these consolidated financial statements were issued and has determined that there are no such events to report.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America and in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. While we believe that the disclosures presented are adequate in order to make the information not misleading, these unaudited quarterly financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K The unaudited consolidated financial statements include the accounts and results of operations of Organogenesis Holdings Inc. and its wholly-owned or controlled subsidiaries of Organogenesis Inc., including Organogenesis GmbH (a Switzerland corporation) and Prime Merger Sub, LLC. All intercompany balances and transactions have been eliminated in consolidation. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. In the opinion of management, the unaudited consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s financial position, results of operations and cash flows at the dates and for the periods indicated. The results for the six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020, any other interim periods, or any future years or periods.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure as of the date of the consolidated financial statements and the reported results of operations during the reporting period. Actual results could differ from those estimates.
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note “2. Significant Accounting Policies” to the Consolidated Financial Statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), which ASU 2018-10, Codification Improvements to Topic 842, Leases ASU 2016-02, and ASU 2018-11, Leases (Topic 842): Targeted Improvements ASU 2016-02, and ASU 2019-01, Leases (Topic 842): Codification Improvements ASU 2016-02 and a right-of-use asset In June 2016, the FASB issued ASU 2016-13 , Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Subsequent ASU 2016-13, the ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments- Credit Losses ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ASU 2019-05, Financial Instruments—Credit Losses (Topic 326)—Targeted Transition Relief ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses ASU 2016-13 and ASU 2016-13 and ASU 2016-13 and

Product and Geographic Sales (T

Product and Geographic Sales (Tables)	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Schedule of Revenue by Product Category	The following tables set forth revenue by product category: Three Months Ended June 30, 2020 2019 Advanced Wound Care $ 59,731 $ 55,211 Surgical & Sports Medicine 9,229 9,737 Total net revenue $ 68,960 $ 64,948 Six Months Ended June 30, 2020 2019 Advanced Wound Care $ 111,019 $ 103,055 Surgical & Sports Medicine 19,673 19,016 Total net revenue $ 130,692 $ 122,071

Accounts receivable, net (Table

Accounts receivable, net (Tables)	6 Months Ended
	Jun. 30, 2020
Receivables [Abstract]
Schedule of accounts receivable	Accounts receivable consisted of the following: June 30, December 31, 2020 2019 Accounts receivable $ 47,952 $ 42,408 Less — allowance for sales returns and doubtful accounts (3,928 ) (3,049 ) $ 44,024 $ 39,359
Schedule of allowance for sales returns and doubtful accounts	The Company’s allowance for sales returns and doubtful accounts was comprised of the following: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Balance at beginning of period $ 3,204 $ 3,292 $ 3,049 $ 3,420 Additions (reductions) 753 103 970 27 Write-offs (29 ) (374 ) (91 ) (426 ) Balance at end of period $ 3,928 $ 3,021 $ 3,928 $ 3,021

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories, net of related reserves for excess and obsolescence, consisted of the following: June 30, December 31, 2020 2019 Raw materials $ 9,591 $ 9,178 Work in process 1,559 781 Finished goods 17,412 12,959 $ 28,562 $ 22,918

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and equipment consisted of the following: June 30, December 31, 2020 2019 Leasehold improvements $ 38,807 $ 36,344 Furniture, computers and equipment 47,352 46,430 86,159 82,774 Accumulated depreciation and amortization (67,604 ) (65,812 ) Construction in progress 34,478 30,222 $ 53,033 $ 47,184

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Identifiable intangible assets consisted of the following as of June 30, 2020: Original Accumulated Net Book Cost Amortization Value Developed technology $ 30,570 $ (12,748 ) $ 17,822 Trade names and trademarks 2,000 (766 ) 1,234 Non-compete 260 (152 ) 108 Total $ 32,830 $ (13,666 ) $ 19,164 Identifiable intangible assets consisted of the following as of December 31, 2019: Original Accumulated Net Book Cost Amortization Value Developed technology $ 30,570 $ (11,266 ) $ 19,304 Trade names and trademarks 2,000 (650 ) 1,350 Non-compete 260 (117 ) 143 Total $ 32,830 $ (12,033 ) $ 20,797

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses and other current liabilities consisted of the following: June 30, December 31, 2020 2019 Accrued personnel costs $ 19,062 $ 17,640 Other 5,626 5,810 $ 24,688 $ 23,450

Long-Term Debt Obligations (Tab

Long-Term Debt Obligations (Tables)	6 Months Ended
	Jun. 30, 2020
Long-term Debt, Unclassified [Abstract]
Schedule of long-term debt obligations	Long-term debt obligations consisted of the following: June 30, December 31, 2020 2019 Line of credit $ 39,353 $ 33,484 Term loan 60,000 50,000 Less debt discount and debt issuance cost (379 ) (366 ) Less current maturities (6,667 ) — Term loan, net of debt discount, debt issuance cost and current maturities $ 52,954 $ 49,634
Schudle of future payments of term loan facility	Future payments of the 2019 Credit Agreement, as of June 30, 2020, are as follows for the calendar years ending December 31: 2020 $ — 2021 16,667 2022 20,000 2023 20,000 2024 42,686 Total $ 99,353

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule Of Common Stock Shares Reserved For Future Issuance	As of June 30, 2020 and December 31, 2019, the Company reserved the following shares of Class A common stock for future issuance: June 30, December 31, 2020 2019 Shares reserved for issuance for outstanding options 7,161,316 6,503,646 Shares reserved for issuance for outstanding restricted stock units 858,095 — Shares reserved for issuance for future grants 6,612,178 9,008,996 Total shares of authorized common stock reserved for future issuance 14,631,589 15,512,642

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of unvested restricted stock units	The activity of restricted stock units is set forth below: Number Weighted Unvested at December 31, 2019 — $ — Granted 873,595 3.81 Vested — — Canceled/Forfeited (15,500 ) 4.04 Unvested at June 30, 2020 858,095 $ 3.81
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity since December 31, 2019: Weighted Average Weighted Remaining Average Contractual Aggregate Number of Exercise Term Intrinsic Shares Price (in years) Value Outstanding as of December 31, 2019 7,179,636 $ 1.98 5.06 $ 20,799 Granted 1,538,723 4.04 Exercised (546,282 ) 1.77 1,552 Canceled / forfeited (334,771 ) 3.48 Outstanding as of June 30, 2020 7,837,306 2.34 5.90 12,933 Options exercisable as of June 30, 2020 5,492,502 1.59 4.44 12,694 Options vested or expected to vest as of June 30, 2020 7,326,832 $ 2.21 5.65 $ 12,904

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following potential shares of Class A common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to the common stockholders of Organogenesis Holdings Inc. for the periods indicated because including them would have had an anti-dilutive effect: Six Months Ended June 30, 2020 2019 Options to purchase common stock 7,837,306 7,328,352 Restricted stock units 858,095 — Warrants to purchase common stock — 17,678,074 8,695,401 25,006,426

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Future Lease Payments	2020 (remaining 6 months) $ 2,396 2021 4,786 2022 4,945 2023 — 2024 9,839 21,966 Less amount representing interest (5,628 ) Present value of minimum lease payments 16,338 Less current maturities (3,327 ) Long-term portion $ 13,011
Schedule Of Operating Leased Assets	2020 (remaining 6 months) $ 2,884 2021 5,627 2022 3,094 2023 2,361 2024 1,224 Thereafter 6,899 $ 22,089

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Organization and Financing
Working capital	$ 51,648		$ 51,648
Cash	40,455		40,455		$ 60,174
Accumulated deficit	192,486		192,486		$ 171,007
Net loss	$ (5,166)	$ (9,649)	(21,479)	$ (25,315)
Cash used in operation			$ (26,618)	$ (21,674)

Product and Geographic Sales -

Product and Geographic Sales - Schedule of Revenue by Product Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total revenue	$ 68,960	$ 64,948	$ 130,692	$ 122,071
Advanced Wound Care
Total revenue	59,731	55,211	111,019	103,055
Surgical and Sports Medicine
Total revenue	$ 9,229	$ 9,737	$ 19,673	$ 19,016

Product and Geographic Sales _2

Product and Geographic Sales - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Significant Accounting Policies [Line Items]
Revenue	$ 68,960	$ 64,948	$ 130,692	$ 122,071
GPO Fees	837	731	$ 1,797	1,111
Sales Revenue
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			1.00%
PuraPly
Significant Accounting Policies [Line Items]
Revenue	$ 28,519	$ 29,691	$ 61,024	$ 55,138

Accounts receivable, net (Detai

Accounts receivable, net (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Receivables [Abstract]
Accounts receivable	$ 47,952	$ 42,408
Less — allowance for sales returns and doubtful accounts	(3,928)	(3,049)
Accounts receivable	$ 44,024	$ 39,359

Accounts receivable, net - Sale

Accounts receivable, net - Sales Returns and Doubtful Accounts (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Balance	$ 3,204	$ 3,292	$ 3,049	$ 3,420
Additions (reductions)	753	103	970	27
Write-offs	(29)	(374)	(91)	(426)
Balance	$ 3,928	$ 3,021	$ 3,928	$ 3,021

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Raw materials	$ 9,591	$ 9,178
Work in process	1,559	781
Finished goods	17,412	12,959
Inventory	$ 28,562	$ 22,918

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Inventory reserve and obsolescence charged to cost of goods	$ 940	$ 265	$ 1,709	$ 523

Property and Equipment, Net (De

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment, Gross	$ 86,159	$ 82,774
Accumulated depreciation and amortization	(67,604)	(65,812)
Property, Plant and Equipment, Net	53,033	47,184
Leasehold improvements
Property, Plant and Equipment, Gross	38,807	36,344
Furniture, computers and equipment
Property, Plant and Equipment, Gross	47,352	46,430
Construction in progress
Property, Plant and Equipment, Gross	$ 34,478	$ 30,222

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Depreciation expense	$ 891	$ 859	$ 1,793	$ 1,761
Leasehold improvements
Capital leases recorded within leasehold improvements	21,689		21,689		$ 21,689
Capital lease accumulated depreciation	$ 14,376		$ 14,376		$ 13,777

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Identifiable intangible assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Original Cost	$ 32,830	$ 32,830
Accumulated Amortization	(13,666)	(12,033)
Net Book Value	19,164	20,797
Developed technology
Original Cost	30,570	30,570
Accumulated Amortization	(12,748)	(11,266)
Net Book Value	17,822	19,304
Trade names and trademarks
Original Cost	2,000	2,000
Accumulated Amortization	(766)	(650)
Net Book Value	1,234	1,350
Non-compete agreements
Original Cost	260	260
Accumulated Amortization	(152)	(117)
Net Book Value	$ 108	$ 143

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Goodwill		$ 25,539		$ 25,539		$ 25,539
Amortization of Intangible Assets		$ 816	$ 1,499	1,633	$ 2,997
Intangible asset purchase, cash paid					250
Intangible asset purchase, remaining payables					$ 500
Developed Technology Rights [Member]
Intangible asset purchase, value	$ 750
Intangible asset purchase, cash paid	$ 250
Intangible asset purchase, remaining payables				$ 500

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued personnel costs	$ 19,062	$ 17,640
Other	5,626	5,810
Total Accrued Expenses and Other Current Liabilities	$ 24,688	$ 23,450

Long-Term Debt Obligations (Det

Long-Term Debt Obligations (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Less current maturities	$ (6,667)
Term loan, net of debt discount, debt issuance cost and current maturities	52,954	$ 49,634
2019 Credit Facility [Member]
Line of credit	39,353	33,484
Term loan	60,000	50,000
Less debt discount and debt issuance cost	(379)	(366)
Less current maturities	(6,667)
Term loan, net of debt discount, debt issuance cost and current maturities	$ 52,954	$ 49,634

Long-Term Debt Obligations - Fu

Long-Term Debt Obligations - Future payments of term loan (Detail) $ in Thousands	Jun. 30, 2020USD ($)
2021	$ 16,667
2022	20,000
2023	20,000
2024	42,686
Total	$ 99,353

Long-Term Debt Obligations - Ad

Long-Term Debt Obligations - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 14, 2019	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Apr. 30, 2018	Apr. 28, 2017	Mar. 21, 2017
Loss on the extinguishment of loan			$ (1,862)
Outstanding borrowings		$ 99,353
ML Agreement
Loss on the extinguishment of loan			$ (1,862)
Repayment under Master Lease Agreement	$ 17,649
2017 Credit Agreement
Letter of credit sub facility	26,541
Additional fund							$ 5,000
Maximum borrowing capacity							35,000
2019 Credit Agreement
Term Loan Facility, financial covenants		maintain Minimum Liquidity equal to the greater of (i) 6 months Monthly Burn and (ii) $10,000.
Maximum borrowing capacity	$ 100,000
ML Agreement
Maximum borrowing capacity								$ 20,000
Percentage of final payment fee								6.50%
ML Agreement | Repaid Before Two Years
Prepayment fees								3.00%
ML Agreement | Repaid After Two Years
Prepayment fees								2.00%
Term Loan | 2017 Credit Agreement
Maximum borrowing capacity							$ 5,000
Term Loan | 2019 Credit Agreement
Debt Instrument final payment		$ 3,900
Debt Issuance Costs, Net		$ 554
Debt Instrument, Basis Spread on Variable Rate	3.75%
Debt Instrument Interest Rate		9.25%
Debt Instrument, Description of Variable Rate Basis	annum interest rate equal to the greater of 3.75% above the Wall Street Journal Prime Rate and 9.25%.
Additional payment in aggregate of the principal amount percentage	6.50%
Outstanding borrowings		$ 60,000
Interest payable non current		1,225			$ 681
Term Loan | 2019 Credit Agreement | Repaid After One year Before Two Years
Prepayment premium percentage	2.50%
Term Loan | 2019 Credit Agreement | Repaid After Two year Before Three Years [Member]
Prepayment premium percentage	1.50%
Term Loan | 2019 Credit Agreement | Repaid After Three Years [Member]
Prepayment premium percentage	0.50%
Term Loan | 2019 Credit Agreement | Tranche One [Member]
Aggregate principal amount	$ 40,000
Term Loan | 2019 Credit Agreement | Tranche Two [Member]
Aggregate principal amount						$ 10,000
Term Loan | 2019 Credit Agreement | Tranche Three [Member]
Aggregate principal amount				$ 10,000
Revolving Credit Facility | 2017 Credit Agreement
Letter of credit sub facility									$ 30,000
Revolving Credit Facility | 2019 Credit Agreement
Letter of credit sub facility	$ 40,000	39,353
Future revolving borrowings		0
Debt Issuance Costs, Net		$ 370
Debt Instrument Interest Rate		5.50%
Advance outstanding amount revolving facility	25.00%
Unused Line Fee	0.25%
Revolving Credit Facility | 2019 Credit Agreement | Repaid After One year Before Two Years
Termination fee percentage	3.00%
Revolving Credit Facility | 2019 Credit Agreement | Repaid After Two year Before Three Years [Member]
Termination fee percentage	2.00%
Revolving Credit Facility | 2019 Credit Agreement | Repaid After Three Years [Member]
Termination fee amount	$ 0

Stockholders' Equity (Detail)

Stockholders' Equity (Detail) - shares	Jun. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Shares reserved for issuance for outstanding options	7,161,316	6,503,646
Shares reserved for issuance for outstanding restricted stock units	858,095
Shares reserved for issuance for future grants	6,612,178	9,008,996
Common Stock, Capital Shares Reserved for Future Issuance	14,631,589	15,512,642

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - $ / shares	Jun. 30, 2020	Dec. 31, 2019	Mar. 24, 2019
Common stock, shares authorized	400,000,000	400,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common Stock, Shares, Issued	106,145,716	105,599,434
Treasury stock	728,548
Put Option
Exercise price of put option			$ 9.28
Common Class A
Common stock, shares authorized	400,000,000
Common stock, par value	$ 0.0001
Common Stock, Shares, Issued	106,145,716
Preferred Stock
Preferred shares, shares authorized	1,000,000
Preferred shares, par value (in dollar per share)	$ 0.0001

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Stock option expiration period			10 years
Share-based compensation expense	$ 469	$ 234	$ 678	$ 458
Fair value of option vested			209	$ 344
Restricted Stock Units (RSUs) [Member]
Unrecognized stock compensation expense	2,245		$ 2,245
Share-based compensation expected to be recognized over a weighted-average period			3 years 5 months 1 day
Restricted stock units issued to employees			873,595
Option Loans
Related Parties Notes Receivable	$ 635		$ 635		$ 635
Number of shares issued as collateral for the option loans	675,990		675,990
Option
Unrecognized stock compensation expense	$ 2,047		$ 2,047
Share-based compensation expected to be recognized over a weighted-average period			2 years 11 months 8 days
Minimum
Stock option granted vesting period			4 years
Maximum
Stock option granted vesting period			5 years
Common Class A | 2018 Stock Incentive Plan
Common stock options authorized	9,198,996		9,198,996

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Unvested Restricted Stock Units (Detail)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Schedule Of Nonvested Restricted Stock Units Activity [Line Items]
Number of Shares | shares	0
Number of Shares, Granted | shares	873,595
Number of Shares, Vested | shares	0
Number of Shares, Canceled/Forfeited | shares	(15,500)
Number of Shares | shares	858,095
Weighted Average Grant Date Fair Value | $ / shares	$ 0
Weighted Average Grant Date Fair Value, Granted | $ / shares	3.81
Weighted Average Grant Date Fair Value, Vested | $ / shares	0
Weighted Average Grant Date Fair Value, Canceled/Forfeited | $ / shares	4.04
Weighted Average Grant Date Fair Value | $ / shares	$ 3.81

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares
Number of Shares Outstanding | shares	7,179,636
Number of Shares Granted | shares	1,538,723
Number of Shares Exercised | shares	(546,282)
Number of Shares Canceled / forfeited | shares	(334,771)
Number of Shares Outstanding | shares	7,837,306	7,179,636
Number of Shares Options Exercisable | shares	5,492,502
Number of Shares Options vested or expected to vest | shares	7,326,832
Weighted Average Exercise Price Outstanding | $ / shares	$ 1.98
Weighted Average Exercise Price Granted | $ / shares	4.04
Weighted Average Exercise Price Exercised | $ / shares	1.77
Weighted Average Exercise Price Cancelled / forfeited | $ / shares	3.48
Weighted Average Exercise Price Outstanding | $ / shares	2.34	$ 1.98
Weighted Average Exercise Price Options Exercisable | $ / shares	1.59
Weighted Average Exercise Price Options Vested or Expected to Vest | $ / shares	$ 2.21
Weighted Average Remaining Contractual Term (in years) Outstanding	5 years 10 months 24 days	5 years 21 days
Weighted Average Remaining Contractual Term (in years) Options Exercisable	4 years 5 months 8 days
Weighted Average Remaining Contractual Term (in years) Options Vested or Expected to Vest	5 years 7 months 24 days
Aggregate Intrinsic Value Outstanding | $	$ 20,799
Aggregate Intrinsic Value Options Exercised | $	1,552
Aggregate Intrinsic Value Outstanding | $	12,933	$ 20,799
Aggregate Intrinsic Value Options Exercisable | $	12,694
Aggregate Intrinsic Value Options Vested or Expected to Vest | $	$ 12,904

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,695,401	25,006,426
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,837,306	7,328,352
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	858,095
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		17,678,074

Commitments and Contingencies_2

Commitments and Contingencies (Schedule of leases payments) (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
2020 (remaining 6 months)	$ 2,396
2021	4,786
2022	4,945
2024	9,839
Total	21,966
Less amount representing interest	(5,628)
Present value of minimum lease payments	16,338
Less current maturities	(3,327)	$ (3,057)
Long-term portion	$ 13,011	$ 14,431

Commitments and Contingencies_3

Commitments and Contingencies (Schedule Of Operating Leased Assets) (Detail) $ in Thousands	Jun. 30, 2020USD ($)
2020 (remaining 6 months)	$ 2,884
2021	5,627
2022	3,094
2023	2,361
2024	1,224
Thereafter	6,899
Total	$ 22,089

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) ft² in Thousands, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 14, 2020USD ($)	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2019USD ($)
Business​ combination ​deferred​ consideration payment						$ 2,500
Business Combination Deferred Consideration							$ 5,000
Accrued Legal Expenses		$ 1,109		$ 1,109			542
Operating Lease, Expense		$ 1,837	$ 1,603	$ 3,351	$ 2,925
Land Subject to Ground Leases | ft²		43,850		43,850
Litigation settlement amount				$ 4,000
Payments for Legal Settlements				2,000
Remaining litigation settlement amount payable		$ 2,000		2,000
Remaining litigation settlement amount payable per quarter		500		500
Gain on litigation settlement				1,295
License agreement with a university
Accrued Royalties		1,187		1,187			1,187
Royalty Expense		0	0	0	0
License agreement with a third party through October 2026
Royalty Expense		839	$ 916	1,819	$ 1,704
CAM Portion of Accrued Rent
Accrued but unpaid capital lease obligations		497		497			503
Dan Road Associates
Capital Leases, Future Minimum Payments, Next Rolling Twelve Months		$ 4,308		$ 4,308
Capital Leases Aggregate Annual Lease Payments Rent Percentage		10.00%		10.00%
Accrued but unpaid capital lease obligations		$ 10,336		$ 10,336			10,336
Accrued Interest		1,195		1,195			717
Dan Road Associates | Interest
Accrued but unpaid capital lease obligations		3,208		3,208			3,512
Dan Road Associates | Principal
Accrued but unpaid capital lease obligations		6,631		6,631			$ 6,321
Norwood Lease
Annual lease payments during the first year		1,052		1,052
Annual lease payments ten year lease term		44		44
Annual lease payments five year lease term		33		33
Security Deposit		526		526
Increase (Decrease) in Security Deposits				263
NuTech Medical
Business Combination Deferred Consideration		$ 7,500		7,500
Under the lease, the Company is required to make monthly rent payments of approximately				$ 21
Consulting service and royalty payment term				15 years
Agreement cancellation charges paid	$ 1,950			$ 1,950

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Net principal and interest receivable	$ 302		$ 302		$ 556
Interest Income	$ 20	$ 20	$ 40	$ 39
Option Loans
Stock Held By Employee	675,990		675,990
Related Parties Notes Receivable	$ 635		$ 635		635
Liquidity Loan to Two Former Employee
Stock Held By Employee	1,739,088		1,739,088
Related Parties Notes Receivable	$ 2,350		$ 2,350		$ 2,350
Maximum | Liquidity Loan and Option Loans
Interest Rate	3.86%		3.86%
Minimum | Liquidity Loan and Option Loans
Interest Rate	2.30%		2.30%